Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Fred Hutchinson Cancer Center Clear all
Completed Not applicable Interventional

Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials

NCT06484595
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Patient Navigation
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

NCT03483675
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Immunosuppressive Therapy, Survey Administration
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

NCT01011075
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Imatinib mesylate, Paclitaxel
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
70 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Albuquerque, New Mexico • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Jun 7, 2026, 4:41 AM EDT
Not yet recruiting Not applicable Interventional

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

NCT07094750
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Collection, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Effects of Cocoa Flavanol on Cognition Assessed Online

NCT04582617
View directory record Official record
Conditions
Aging, Cognitive Change
Interventions
Cocoa Extract, Cocoa Extract Placebo, Multivitamin, Multivitamin placebo
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
65 Years and older
Enrollment
3,959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 2 Interventional Results available

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

NCT00914940
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation
Drug · Radiation · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT00217555
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
gemcitabine hydrochloride, topotecan hydrochloride
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00062140
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
cyclophosphamide, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

NCT00054340
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Jun 7, 2026, 4:41 AM EDT
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography, Multigated Acquisition Scan, Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

NCT04496219
View directory record Official record
Conditions
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Superficial Bladder Urothelial Carcinoma
Interventions
Acupuncture Therapy, BCG Solution, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Device · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Not applicable Interventional

Screening Mammography and Latinas: A Multilevel Intervention

NCT02010008
View directory record Official record
Conditions
Breast Cancer
Interventions
Motivational Interviewing Intervention
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

NCT03074318
View directory record Official record
Conditions
Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
Interventions
Avelumab, Trabectedin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jun 7, 2026, 4:41 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers

NCT04260776
View directory record Official record
Conditions
Social Anxiety Disorder, Tobacco Use Disorder
Interventions
Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages, Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages, Phase 2: re-engagement text messages, Phase 2: re-engagement emails
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Not applicable Interventional

Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up

NCT00697047
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Automated Mailing, Automated Mailing Plus Assisted, Auto Plus Assisted Plus Navigation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 73 Years
Enrollment
4,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jun 7, 2026, 4:41 AM EDT
Not yet recruiting Not applicable Interventional

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT05874297
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Best Practice, Internet-Based Intervention, Questionnaire Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

NCT00470561
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2010 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

NCT01465386
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Interventions
bortezomib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00027924
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclosporine, fludarabine phosphate, methotrexate, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 1 Interventional Results available

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

NCT04893018
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
Interventions
Efineptakin alfa
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
San Francisco, California • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Jun 7, 2026, 4:41 AM EDT
Recruiting Not applicable Interventional

Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies

NCT04829136
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Kate Farms 1.0, Standard of Care Nutritional Support, Survey Administration, Dietary Supplement, Biospecimen Collection, Electronic Health Record Review, Fiber and Dietary Assessments
Dietary Supplement · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

NCT04103879
View directory record Official record
Conditions
High Risk Hematological Malignancy, Cord Blood Transplant
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Not yet recruiting Phase 1 Interventional

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
Procedure · Biological · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Not applicable Interventional

Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

NCT01758484
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
palliative care, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jun 7, 2026, 4:41 AM EDT